Abstract: Provided is a method of treating an immune system disorder not involving T cell proliferation, comprising administering to the animal an immunotoxin comprising a mutant diphtheria toxin moiety linked to an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof under conditions such that the disorder is treated. Thus, the present method can treat graft-versus-host disease.
Type:
Grant
Filed:
April 15, 1997
Date of Patent:
August 15, 2000
Assignees:
The United States of America as represented by the Department of Health and Human Services, The UAB Research Foundation
Abstract: The invention described methods for identifying a molecule of interest, as well as nucleic acid molecules which encode it, and binding partners for it. A cDNA library from a cell expressing the target is prepared, and expressed in host cells. Lysates of the host cells are screened with a sample, treated to remove interfering binding partners. The treatment involves contact of the sample to lysates of untransfected host cells, and host cells transfected or transformed with the same vector used to make the cDNA library. Also a part of the invention are antigens and cDNA identified using the methodology.
Abstract: The present invention relates to methods of inducing neurite outgrowth in the central nervous system by antagonizing neural growth inhibitory factors. More particularly, the present invention is directed to use of antibodies to the central nervous system (CNS) myelin associated proteins; such antibodies can be used in the diagnosis and therapies of nerve damage resulting from trauma, infarction, and degenerative disorders of the CNS. In a specific embodiment of the invention, the monoclonal antibody IN-1 may be used to promote neurite outgrowth of nerve fibers over long distances in spinal cord lesions.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
August 15, 2000
Assignee:
Erziehungsdirektion of the Canton Zurich
Inventors:
Martin E. Schwab, Pierenrico W. Caroni, Paolo A. Paganetti
Abstract: The present invention provides isolated nucleic acids encoding alpha9 nicotinic acetylcholine receptor subunit and receptor subunit protein encoded thereby. Also provided are vectors containing the invention nucleic acids, host cells transformed therewith, alpha9 nicotinic acetylcholine receptor subunit and functional nicotinic acetylcholine receptors comprising at least one alpha9 subunit expressed recombinantly in such host cells as well as transgenic non-human mammals that express the invention receptor subunit and mutants thereof. Receptors of the invention comprise at least one alpha9 nicotinic acetylcholine subunit and form cationic channels activated by acetylcholine, but blocked by nicotine and muscarine. The invention also provides methods for identifying compounds that modulate the ion channel activity of the functional invention receptors containing at least one invention subunit.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
August 8, 2000
Assignee:
The Salk Institute for Biological Studies
Inventors:
Ana Belen Elgoyhen, David S. Johnson, James Richard Boulter, Stephen Fox Heinemann
Abstract: Monoclonal antibodies which react specifically to Fc receptor of human effector cells are disclosed. Binding of the antibodies to the receptor is not blocked by human immunoglobulin G. The antibodies are useful for targeting human effector cells (e.g. macrophages) against a target cell (e.g. a cancer cell, an infectious agent, etc.) For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can be used to kill target cells by cell mediated antibody dependent cytolysis.
Type:
Grant
Filed:
June 2, 1997
Date of Patent:
August 1, 2000
Assignee:
Medarex
Inventors:
Michael W. Fanger, Paul M. Guyre, Clark L. Anderson
Abstract: Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications utilizing the TGF-B monoclonal antibody are also disclosed.
Type:
Grant
Filed:
June 15, 1998
Date of Patent:
July 18, 2000
Inventors:
James R. Dasch, Doran R. Pace, III, Wendy O. Waegell
Abstract: Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as M. catarrhalis or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor proteins Tbp1 and Tbp2 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.
Type:
Grant
Filed:
March 8, 1996
Date of Patent:
July 18, 2000
Assignee:
Connaught Laboratories Limited
Inventors:
Lisa E. Myers, Anthony B. Schryvers, Robin E. Harkness, Sheena M. Loosmore, Run-Pan Du, Yan-Ping Yang, Michel H. Klein
Abstract: The present invention generally relates to protein binding fragments of gravin and polynucleotides encoding these fragments. The protein binding fragments include fragments which bind to the Type II regulatory subunit of cAMP-dependent protein kinase or protein kinase C. This invention further provides antibodies to the protein binding fragments and assays for identifying compounds which modulate the binding of gravin to the binding protein.
Type:
Grant
Filed:
December 19, 1997
Date of Patent:
July 18, 2000
Assignee:
Oregon Health Science University
Inventors:
John D. Scott, J. Brian Nauert, Theresa M. Klauck
Abstract: The present invention provides polynucleotides which identify and encode a novel human nm23-like protein (H-nm23). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding H-nm23 and for a method for producing the protein. The invention also provides for the use of substantially purified H-nm23 for the treatment of diseases associated with the expression of H-nm23. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotides which hybridize with naturally occurring sequences encoding H-nm23 and antibodies which specifically bind to the protein.
Abstract: An aqueous or aqueous/alcoholic cosmetic composition comprising an aqueous dispersion of insoluble particles of a non-ionic film-forming polymer, the polymer particles being at a concentration greater than 15% by weight with respect to the total weight of the composition and the glass transition temperature of the polymer particles of the composition ranging from 15 to 35.degree. C. and a process for the cosmetic treatment of keratinous substances using these compositions.
Abstract: A drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation, as well as a model animal of fibrinoid formation or thrombus formation in the lung is disclosed. The drug for preventing and treating diseases caused by fibrinoid formation or thrombus formation in the lung according to the present invention comprises an inhibitor of interleukin 6 as an effective ingredient. The model animal of the diseases caused by fibrinoid formation or thrombus formation in the lung is a rat in which fibrinoid formation or thrombus formation actually occurs by induction with interleukin 6.
Abstract: Mammalian deep orange tumor suppressor genes are disclosed. Mammalian deep orange genes and proteins can be used as therapeutics, as diagnostic tools, and in making animal models. The genes can be used to identify a q13 region of a human chromosome 15 and a central region of a mouse chromosome 2.
Abstract: Individuals having tumors are treated with pharmaceutical compositions comprising expression vectors, preferably adenovirus or retroviruses, comprising nucleic acid molecules encoding soluble IGF-1R. Such vectors express soluble IGF-1R in tumor cells resulting in reversal of the transformed phenotype, induction of apoptosis, and inhibition of tumorigenesis.
Type:
Grant
Filed:
November 13, 1996
Date of Patent:
July 4, 2000
Assignee:
Thomas Jefferson University
Inventors:
Renato Baserga, Mariana Resnicoff, Consuelo D'Ambrosio, Andre Ferber
Abstract: The present invention provides a method of detecting active antibody production in a blood sample by contacting, in the presence and absence of protein synthesis inhibitor, aliquots of the sample with a solid phase under conditions which permit antibody production and secretion by the lymphocytes; detecting in solution, binding of antibody to the antigen(s) on the solid phase; and comparing the antibody binding in the presence or absence of protein synthesis inhibitor, whereby to obtain a determination of the amount of active antibody secretion in response to the antigen(s); and kits for performing the method. The method may also be modified to allow detection of non-specific infection indicators.
Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
Type:
Grant
Filed:
September 10, 1997
Date of Patent:
June 27, 2000
Assignees:
Vion Pharmaceuticals, Inc., Yale University
Abstract: The invention comprises the nucleotide sequences comprising the FIPV S gene, or a fragment of this gene, which are modified in at least one of the antigenic regions A1 and A2 which are involved in enhancement, as well as the use of these sequences for the expression of modified proteins, and for the construction of recombinant viruses or expression plasmids, and the use of the recombinant viruses as vaccines against feline infectious peritonitis, the use of the expression plasmids as immunizing composition by direct injection of the said plasmids into cats, and the use of the modified proteins as vaccine.
Abstract: The invention provides three human proteins associated with cell proliferation, referred to collectively as "APOP" and individually as "APOP-1", "APOP-2", and "APOP-3", and polynucleotides which identify and encode APOP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for preventing and treating disorders associated with expression of APOP.
Type:
Grant
Filed:
December 4, 1997
Date of Patent:
June 27, 2000
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Henry Yue, Preeti Lal, Purvi Shah, Neil C. Corley
Abstract: The invention relates to a nucleic acid construct for expressing an active substance which is activated by an enzyme which is released from mammalian cells, which construct comprises the following components: a) at least one promoter element, b) at least one DNA sequence which encodes an active compound (protein B) c) a least one DNA sequence which encodes an amino acid sequence (part structure C) which can be cleaved specifically by an enzyme which is released from a mammalian cell, and d) at least one DNA sequence which encodes a peptide or protein (part structure D) which is bound to the active compound (protein B) by way of the cleavable amino acid sequence (part structure C) and inhibits the activity of the active compound (protein B), and also to the use of the nucleic acid construct for preparing a drug for treating diseases.
Type:
Grant
Filed:
January 16, 1998
Date of Patent:
June 27, 2000
Assignee:
Hoechst Aktiengesellschaft AG
Inventors:
Hans Heinrich Heidtmann, Rolf Mueller, Hans-Harald Sedlacek
Abstract: The invention provides a human human brain-associated protein (HBAP-1) and polynucleotides which identify and encode HBAP-1. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of HBAP-1.
Type:
Grant
Filed:
May 1, 1998
Date of Patent:
June 27, 2000
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Sven Henrichwark, Janice Au-Young, Karl J. Guegler, Neil C. Corley, Mariah R. Baughn
Abstract: Novel fibronectin binding protein B polypeptides and DNA (RNA) encoding such novel fibronectin binding protein B and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such novel fibronectin binding protein B for the treatment of infection, particularly bacterial infections. Antagonists against such novel fibronectin binding protein B and their use as a therapeutic to treat infections, particularly bacterial infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of novel fibronectin binding protein B nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding novel fibronectin binding protein B family and for detecting the polypeptide in a host.
Type:
Grant
Filed:
December 4, 1998
Date of Patent:
June 20, 2000
Assignee:
SmithKline Beecham, p.l.c.
Inventors:
John Edward Hodgson, Martin Karl Russell Burnham